Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Brief summary
This is a multi-center, randomized, double-blind, parallel group, chronic dosing, active-controlled, 28-week safety extension study of the two pivotal 24-week safety and efficacy studies (Studies PT003006 and PT003007). This study is designed to assess the long-term safety and tolerability of Glycopyrrolate (GP) and Formoterol Fumarate (FF) combination (GFF) metered dose inhaler (MDI), GP MDI, and FF MDI in subjects with moderate to very severe COPD over a total observation period of 52 weeks. Open-label Spiriva is included as an active control. To be eligible for this study, a subject must complete participation in Study PT003006 (NCT01854645) or Study PT003007 (NCT01854658).
Interventions
DRUGGFF MDI (PT 003)
GFF MDI administered as two puffs BID
DRUGGP MDI (PT001)
GP MDI administered as two puffs BID
DRUGFF MDI (PT005)
FF MDI administered as two puffs BID
DRUGOpen-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Sponsors
Pearl Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Participant in/completion of previous 24-week PINNACLE Phase III Trial. * Male or female subjects at least 40 years of age and no older than 80 at Visit 1. * Subjects with an established clinical history of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) * Current or former smokers with a history of at least 10 pack-years of cigarette smoking. * Subjects with FEV1/forced vital capacity (FVC) ratio of \<0.70 and FEV1 \<80% predicted normal and ≥750 mL if FEV1 \<30% of predicted normal value. * Subjects willing and, in the opinion of the investigator, able to adjust current COPD therapy as required by the protocol Key
Exclusion criteria
* Significant diseases other than COPD, i.e. disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study * Current diagnosis of asthma or alpha-1 antitrypsin deficiency * Other active pulmonary disease such as active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, idiopathic interstitial pulmonary fibrosis, primary pulmonary hypertension, or uncontrolled sleep apnea * Hospitalized due to poorly controlled COPD within 3 months prior to screening or during the Screening Period * Poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to screening or during the Screening Period * Lower respiratory tract infections that required antibiotics within 6 weeks prior to screening or during the Screening Period * Unstable ischemic heart disease, left ventricular failure, or documented myocardial infarction within 12 months of enrollment. * Recent history of acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft within the past three months * Congestive heart failure (CHF) New York Heart Association (NYHA) Class III/IV) * Clinically significant abnormal 12-lead electrocardiogram (ECG) * Abnormal liver function tests defined as alanine transaminase (ALT), aspartate transaminanse (AST), or total bilirubin ≥ 1.5 times upper limit of normal at Visit 1 and on repeat testing * Cancer not in complete remission for at least five years * History of hypersensitivity to β2-agonists, glycopyrronium or other muscarinic anticholinergics, lactose/milk protein or any component of the MDI Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks | Baseline and Weeks 2 to 52 | Change From Baseline in Morning Pre-Dose Trough FEV1 Over 52 Weeks as a Model-Based Average (ITT Population). FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks | Baseline and Weeks 4 to 52 | SAC TDI focal score over 52 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. |
| Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing | Baseline and Weeks 2 to 52 | Peak change from Baseline FEV1 Over 52 Weeks is a Model-Based Average (ITT Population). Peak FEV1 was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average Peak FEV1 post-baseline. |
| Change From Baseline in SGRQ Total Score | Baseline and Weeks 12 to 52 | The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (best possible health status) to 100 (worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life. SGRQ Total Score was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 12 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average SGRQ Total Score post-baseline. |
| Change From Baseline in Average Daily Rescue Ventolin Use | Baseline through Week 52 | Subjects recorded in their diary the number of puffs of rescue Ventolin HFA taken on each study day. The subject's average daily number of puffs of rescue Ventolin HFA was calculated over the entire 52-week treatment period. Missing values were ignored in both the numerator and denominator. Diary data recorded during the last 7 days of the 10-14 day screening period were used to calculate the baseline average. Change in rescue Ventolin HFA use was calculated by subtracting the baseline average from the 52-week average. |
Countries
Australia, New Zealand, United States
Participant flow
Recruitment details
Conducted at 205 sites from November 2013- December 2014. The entire study period was a maximum of 30 weeks.
Pre-assignment details
Study PT003008 was an extension of Studies NCT01854645 and NCT01854658. A proportion of subjects on active treatment were randomly invited to participate. Analysis of Study PT003008 included all subjects enrolled in the lead-in studies to avoid bias. Hence, the number analyzed will be greater than the 892 subjects enrolled into the extension.
Participants by arm
| Arm | Count |
|---|---|
| GFF MDI (PT003) GFF MDI 14.4/9.6 mcg | 1,035 |
| GP MDI (PT001) GP MDI 14.4 mcg | 888 |
| FF MDI (PT005) FF MDI 9.6 mcg | 884 |
| Spiriva® Handihaler® (Open-label) Open-label tiotropium bromide inhalation powder 18 mcg | 450 |
| Total | 3,257 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Administrative Reasons | 1 | 0 | 0 | 4 |
| Overall Study | Adverse Event | 12 | 7 | 4 | 3 |
| Overall Study | Lack of Efficacy | 2 | 1 | 2 | 0 |
| Overall Study | Lost to Follow-up | 1 | 3 | 2 | 4 |
| Overall Study | No Completion Status | 0 | 1 | 0 | 0 |
| Overall Study | Physician Decision | 0 | 1 | 1 | 0 |
| Overall Study | Protocol Specified Criteria | 10 | 4 | 3 | 6 |
| Overall Study | Withdrawal by Subject | 11 | 10 | 14 | 7 |
Baseline characteristics
| Characteristic | FF MDI (PT005) | GFF MDI (PT003) | GP MDI (PT001) | Spiriva® Handihaler® (Open-label) | Total |
|---|---|---|---|---|---|
| Age, Continuous | 62.8 years STANDARD_DEVIATION 8.1 | 62.7 years STANDARD_DEVIATION 8.3 | 62.8 years STANDARD_DEVIATION 8.4 | 62.9 years STANDARD_DEVIATION 8.6 | 62.8 years STANDARD_DEVIATION 8.3 |
| Sex: Female, Male Female | 392 Participants | 473 Participants | 392 Participants | 182 Participants | 1439 Participants |
| Sex: Female, Male Male | 492 Participants | 562 Participants | 496 Participants | 268 Participants | 1818 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 109 / 1,036 | 77 / 890 | 90 / 890 | 51 / 451 |
| serious Total, serious adverse events | 114 / 1,036 | 90 / 890 | 78 / 890 | 49 / 451 |
Outcome results
Primary
Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks
Change From Baseline in Morning Pre-Dose Trough FEV1 Over 52 Weeks as a Model-Based Average (ITT Population). FEV1 was assessed at multiple time points post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.
Time frame: Baseline and Weeks 2 to 52
Population: Subjects in the ITT population from the lead-in studies who had data for the parameter.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GFF MDI (PT003) | Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks | 0.133 Liters |
| GP MDI (PT001) | Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks | 0.076 Liters |
| FF MDI (PT005) | Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks | 0.068 Liters |
| Spiriva® Handihaler® (Open-label) | Change From Baseline in Morning -Pre-dose Trough FEV1 Over 52 Weeks | 0.107 Liters |
Secondary
Change From Baseline in Average Daily Rescue Ventolin Use
Subjects recorded in their diary the number of puffs of rescue Ventolin HFA taken on each study day. The subject's average daily number of puffs of rescue Ventolin HFA was calculated over the entire 52-week treatment period. Missing values were ignored in both the numerator and denominator. Diary data recorded during the last 7 days of the 10-14 day screening period were used to calculate the baseline average. Change in rescue Ventolin HFA use was calculated by subtracting the baseline average from the 52-week average.
Time frame: Baseline through Week 52
Population: Subjects in the ITT population from the lead-in studies who had data for the parameter
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GFF MDI (PT003) | Change From Baseline in Average Daily Rescue Ventolin Use | -0.9 Puffs per day |
| GP MDI (PT001) | Change From Baseline in Average Daily Rescue Ventolin Use | -0.4 Puffs per day |
| FF MDI (PT005) | Change From Baseline in Average Daily Rescue Ventolin Use | -0.7 Puffs per day |
| Spiriva® Handihaler® (Open-label) | Change From Baseline in Average Daily Rescue Ventolin Use | -0.4 Puffs per day |
Secondary
Change From Baseline in SGRQ Total Score
The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (best possible health status) to 100 (worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life. SGRQ Total Score was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 12 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average SGRQ Total Score post-baseline.
Time frame: Baseline and Weeks 12 to 52
Population: Subjects in the ITT population from the lead-in studies who had data for the parameter
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GFF MDI (PT003) | Change From Baseline in SGRQ Total Score | -3.3 Scores on a scale |
| GP MDI (PT001) | Change From Baseline in SGRQ Total Score | -1.9 Scores on a scale |
| FF MDI (PT005) | Change From Baseline in SGRQ Total Score | -2.4 Scores on a scale |
| Spiriva® Handihaler® (Open-label) | Change From Baseline in SGRQ Total Score | -2.9 Scores on a scale |
Secondary
Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing
Peak change from Baseline FEV1 Over 52 Weeks is a Model-Based Average (ITT Population). Peak FEV1 was assessed at multiple visits post-baseline, and a model-based average of all visits starting from Week 2 through week 52 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average Peak FEV1 post-baseline.
Time frame: Baseline and Weeks 2 to 52
Population: Subjects in the ITT population from the lead-in studies who had data for the parameter.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GFF MDI (PT003) | Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing | 0.363 Liters |
| GP MDI (PT001) | Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing | 0.234 Liters |
| FF MDI (PT005) | Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing | 0.275 Liters |
| Spiriva® Handihaler® (Open-label) | Peak Change From Baseline in FEV1 Within 2 Hrs Post-dosing | 0.270 Liters |
Secondary
Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks
SAC TDI focal score over 52 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9.
Time frame: Baseline and Weeks 4 to 52
Population: Subjects in the ITT population from the lead-in studies who had data for the parameter.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| GFF MDI (PT003) | Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks | 0.5 Scores on a scale |
| GP MDI (PT001) | Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks | 0.3 Scores on a scale |
| FF MDI (PT005) | Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks | 0.3 Scores on a scale |
| Spiriva® Handihaler® (Open-label) | Self-Administered Computerized (SAC) TDI Focal Score Over 52 Weeks | 0.4 Scores on a scale |